Blue Jet Healthcare Ltd Reports Record Q2 Revenue, Margins Ease

Blue Jet Healthcare Ltd reported record Q2 FY27 revenue from operations of ₹375.74 crore, up 127.1% year on year, while gross margin declined to 48.5% from 53.2% in the preceding quarter. The September 2026 quarter also delivered EBITDA of ₹118.8 crore and net profit of ₹102.52 crore, supported by growth in pharma intermediates, APIs and contrast media intermediates.

What did Blue Jet Healthcare report for Q2 FY27?

Blue Jet Healthcare reported its highest quarterly revenue, with revenue from operations rising 28.2% sequentially from ₹293.1 crore in Q1 FY27 and 127.1% from ₹165.5 crore in Q2 FY26. Total income for the quarter was ₹401.95 crore. The board approved the unaudited standalone results for the quarter and half year ended September 30, 2026, on November 5, 2026.

EBITDA increased 21% sequentially to about ₹118.8 crore and rose 116.1% from the year-earlier quarter. EBITDA margin stood at 31.6%, compared with 33.2% in Q2 FY26. Profit after tax was ₹102.52 crore, up 96.6% year on year and 31% from the previous quarter. No exceptional items were reported, and the statutory auditor's limited review did not identify matters indicating material misstatement or non-compliance with required disclosures.

Which businesses drove Blue Jet Healthcare's revenue growth?

Blue Jet Healthcare said growth was led by pharma intermediates and active pharmaceutical ingredients, or APIs, alongside contrast media intermediates. Pharma intermediates and APIs recorded year-on-year growth of 322.1%, while contrast media intermediates grew 79.6%. These businesses helped lift quarterly revenue to a record level despite uneven movement across the product portfolio.

On a sequential basis, contrast media grew 25% and the PI API segment grew 52%. Artificial sweeteners, however, declined 30% sequentially. The contrast between strong growth in pharmaceutical-facing categories and the decline in sweeteners is important because the company has exposure to multiple specialty product lines, whose quarterly contribution can vary with customer orders and product mix.

For the first half of FY27, Blue Jet Healthcare reported revenue of ₹668.9 crore, up 29% year on year, and profit after tax of ₹180.8 crore. H1 gross margin was 50.6%, compared with 53.7% in the comparative period cited by the company. The half-year figures show that the second-quarter revenue acceleration occurred alongside a lower gross-margin profile.

Why did Blue Jet Healthcare's gross margin decline?

Blue Jet Healthcare's gross margin declined because prices of raw materials, reagents, solvents and catalysts increased, including costs linked to West Asia. Gross margin was 48.5% in Q2 FY27, down 4.7 percentage points from 53.2% in Q1 FY27 and down from 65.0% in Q2 FY26, according to the earnings summary.

The company still reported a 31.6% EBITDA margin, but this was 1.6 percentage points below the 33.2% margin reported a year earlier. The movement indicates that strong revenue growth did not fully offset the effect of higher inputs at the gross-profit level. It also distinguishes the company's operating profitability from gross margin, as these measures reflect different cost layers.

Management did not provide numerical forward guidance. It indicated that margin recovery depends on price increases expected from Q3 FY27. The available disclosure does not specify the size of any price hike, the timing of customer acceptance, or the resulting effect on quarterly margins. Investors therefore have a stated management lever to monitor, rather than a quantified margin target.

What is the Vizag expansion plan?

Blue Jet Healthcare said its Vizag capacity is supported by existing clients with firm commitments and is intended to produce an adjacent high-intensity sweetener. Chief Operating Officer V.K. Singh said that virtually no company in India manufactures the product described during the earnings call.

Management positioned the project as an extension of the company's sweetener portfolio rather than as a replacement for its existing products. It also said it expected relatively quick customer engagement for the new capacity. However, the disclosed material does not provide investment cost, capacity size, commissioning date, revenue contribution or a specific financial target for the Vizag facility.

The expansion discussion comes after artificial sweeteners recorded a 30% sequential decline in Q2 FY27. The company has not linked that quarterly decline directly to the Vizag project. The available comments instead indicate that the proposed product is a different, adjacent high-intensity sweetener aimed at a category with limited domestic manufacturing presence.

How do the results affect Blue Jet Healthcare investors?

Blue Jet Healthcare's results provide evidence of substantial sales and profit growth in Q2 FY27, with revenue more than doubling from the year-earlier period and PAT rising 96.6%. For investors, the principal financial trade-off in the quarter was that a record ₹375.74 crore of revenue was accompanied by lower gross and EBITDA margins.

The company generated EBITDA of ₹118.8 crore and PAT of ₹102.52 crore while operating margin remained above 30%. But the quarter's gross-margin decline was significant, reflecting cost inflation in materials and processing inputs. Any effect of planned price hikes will depend on execution and customer acceptance, neither of which was quantified in the disclosures.

For industry operations, the results underline the importance of input-cost management in specialty pharmaceutical intermediates, APIs and related chemical products. Blue Jet Healthcare's product mix also produced diverging sequential trends, with contrast media and PI API expanding while artificial sweeteners contracted. The announced Vizag capacity adds an operational development to track, but its financial contribution has not been disclosed.

Conclusion

Blue Jet Healthcare delivered record Q2 FY27 revenue of ₹375.74 crore, driven by strong pharma intermediates, API and contrast media performance. EBITDA and net profit also rose sharply from a year earlier, while higher costs for raw materials, reagents, solvents and catalysts reduced gross margin to 48.5% and EBITDA margin to 31.6%.

The next items to watch are management's expected Q3 price hikes, the movement in gross margin, and details on the Vizag high-intensity sweetener capacity. The company has cited firm customer commitments for the facility, but has not disclosed its cost, commissioning schedule, capacity or expected revenue contribution.